tag:blogger.com,1999:blog-8366969.post7043409284859516628..comments2023-07-19T06:06:33.012-07:00Comments on Moe's misunderestimations: Tumor Treating Fields--a promising new treatment for many kinds of cancer.moe99http://www.blogger.com/profile/02730518982394086828noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-8366969.post-57682830556764367742012-02-01T08:06:07.528-08:002012-02-01T08:06:07.528-08:00Some results evidently have been presented at meet...Some results evidently have been presented at meetings. These links were accessed from the company’s (NovoCure’s) website (http://www.novocure.com/publication.php?ID=2)<br /><br />I’ve just reproduced the titles, authors, and conclusions; there’s a little more info in the complete abstracts online. <br /><br />http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html<br /><br />Ann Oncol (2010) 21(suppl 8): viii122-viii161.<br /><br />371PD A PHASE II STUDY OF TUMOR TREATING FIELDS<br />(TTFIELDS) IN COMBINATION WITH PEMETREXED FOR<br />ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)<br />M. Pless1, D.C. Betticher2, M. Buess3, R. von Moos4, U. Weinberg5, E. Kirson5,<br />Y. Palti6<br />1Oncology, Kantonsspital Winterthur, Winterthur/SWITZERLAND, 2Hospital of<br />Fribourg, Fribourg/SWITZERLAND, 3Oncology, Hospital St. Clara Basel, Basel/<br />SWITZERLAND, 4Kantonsspital Graubu¨nden, Chur/SWITZERLAND, 5RandD,<br />NovoCure, Haifa/ISRAEL, 6NovoCure, Haifa/ISRAEL<br /><br />Conclusions: In addition to being well tolerated and safe when given together with<br />Pemetrexed, efficacy endpoints were remarkably high compared to historical data for<br />Pemetrexed alone. These results indicate TTFields could be considered as a potential<br />future treatment for patients with advanced NSCLC, in combination with chemotherapy.<br />Disclosure: U. Weinberg: Dr. Uri Weinberg works for NovoCure.; E. Kirson: Dr. Eilon<br />Kirson works for NovoCure.; Y. Palti: Prof. Yoram Palti founded NovoCure. All other<br />authors have declared no conflicts of interest.<br /><br />Poster Presented at European Respiratory Society Annual Congress, September 18-22, 2010.<br /><br />http://www.ersnet.org/learning_resources_player/abstract_print_10/files/64.pdf<br /><br />64. Treatmentoflungcancer<br />363<br />An open label pilot study of tumor treating fields(TTFields) in combination<br />With pemetrexed (Pem) for advanced non-small cell lungcancer (NSCLC)<br />UriWeinberg2 , IsabelleFresard1, MarcKueng1, RichardCathomas3,<br />MartinBuess4, MiklosPless5, YoramPalti2 , EilonKirson2, DanielBetticher1.<br />1Internal Medicine, HFR Fribourg, Cantonal Hospital, Fribourg, Switzerland;<br />2 Biotechnology, NovoCureLtd, MatamCenter, Haifa, Israel; <br />3 InternalMedicine,Cantonal Hospital of Graubünden, Chur, Switzerland; <br />4 Oncology,CCRC Universit yHospital of Basel, Basel, Switzerland; <br />5 Internal Medicine,Cantonal Hospital of Winterthur, Winterthur,Switzerland<br /><br />Conclusions: TTFields in combination with Pem is a safe treatment for advanced NSCLC pts with promising results which deserve further investigation in larger trials.<br /><br />Again, not promoting this--just providing info.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8366969.post-69392308652286625862012-01-31T17:01:47.323-08:002012-01-31T17:01:47.323-08:00Some results evidently have been presented at meet...Some results evidently have been presented at meetings. These links were accessed from the company’s (NovoCure’s) website (http://www.novocure.com/publication.php?ID=2)<br /><br />http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html<br /><br />Ann Oncol (2010) 21(suppl 8): viii122-viii161.<br /><br />371PD A PHASE II STUDY OF TUMOR TREATING FIELDS<br />(TTFIELDS) IN COMBINATION WITH PEMETREXED FOR<br />ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)<br />M. Pless1, D.C. Betticher2, M. Buess3, R. von Moos4, U. Weinberg5, E. Kirson5,<br />Y. Palti6<br />1Oncology, Kantonsspital Winterthur, Winterthur/SWITZERLAND, 2Hospital of<br />Fribourg, Fribourg/SWITZERLAND, 3Oncology, Hospital St. Clara Basel, Basel/<br />SWITZERLAND, 4Kantonsspital Graubu¨nden, Chur/SWITZERLAND, 5RandD,<br />NovoCure, Haifa/ISRAEL, 6NovoCure, Haifa/ISRAEL<br /><br />Results: 41 patients, including 7 (17.1%) with squamous cell carcinoma patients and<br />30 (73%) with stage IV disease, were enrolled. Median age was 63 years (range 44-78)<br />and 7 (17%) had ECOG of 2. Patients received a median of 4 courses of pemetrexed<br />(Range 1-33). The device was well tolerated and the average daily use was 11.2 hours -<br />83% of patients received at least one 3-week TTFields course and had a median of<br />4.2 courses of TTFields (range 1-32) for a cumulative time of over 720 weeks. None of<br />the SAE’s reported was TTFields-related. The only device related AE seen in patients<br />was mild to moderate dermatitis under the electrodes reported in 14 patients, which<br />usually improved with topical steroid use. Median systemic PFS was 22 weeks and local<br />PFS in the lungs and abdomen was 28 weeks. Median OS was 13.8 months and 1-year<br />survival 57%. 6 patients (14.6%) had a radiological PR and 16 SD (39%).<br /><br />Conclusions: In addition to being well tolerated and safe when given together with<br />Pemetrexed, efficacy endpoints were remarkably high compared to historical data for<br />Pemetrexed alone. These results indicate TTFields could be considered as a potential<br />future treatment for patients with advanced NSCLC, in combination with chemotherapy.<br />Disclosure: U. Weinberg: Dr. Uri Weinberg works for NovoCure.; E. Kirson: Dr. Eilon<br />Kirson works for NovoCure.; Y. Palti: Prof. Yoram Palti founded NovoCure. All other<br />authors have declared no conflicts of interest.<br /><br />Poster Presented at European Respiratory Society Annual Congress, September 18-22, 2010.<br /><br />http://www.ersnet.org/learning_resources_player/abstract_print_10/files/64.pdf<br /><br />64. Treatmentoflungcancer<br />363<br />An openlabelpilotstudyoftumortreating fields(TTFields)incombination<br />withpemetrexed(Pem)foradvancednon-smallcelllungcancer(NSCLC)<br />UriWeinberg2 , IsabelleFresard1, MarcKueng1, RichardCathomas3,<br />MartinBuess4, MiklosPless5, YoramPalti2 , EilonKirson2, DanielBetticher1.<br />1InternalMedicine,HFRFribourg,CantonalHospital,Fribourg,Switzerland;<br />2Biotechnology,NovoCureLtd,MatamCenter,Haifa,Israel; 3InternalMedicine,<br />CantonalHospitalofGraubünden,Chur,Switzerland; 4Oncology,CCRC<br />UniversityHospitalofBasel,Basel,Switzerland; 5InternalMedicine,Cantonal<br />HospitalofWinterthur,Winterthur,Switzerland<br /><br />Results: Study pts received the TTFields together with Pem for over 435weeks (cumulativelyfor all pts).The median observation time was 8 months.Toxicity:5 SAE were reported,none of which hwereTTFields-norPem-related.There were no side effects including cardiac arrhythmia or myelosuppression induced by the TTFields.The onlyTTFields-related adverse event was dermatitis in areas covered by the electrodes. Activity: 2pts(17%) had partial response and 7(58%) had stable disease(clinical benefit in 65% of pts). Progression-free survival at 6 months for all pts was 50%,and 1-yea survival was 43%. <br /><br />Conclusions: TTFields in combination with Pem is a safe treatment for advanced NSCLC pts with promising results which deserve further investigation in larger trials. <br /><br />More complete, easier to read if you go to the links.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8366969.post-24005721341726895902012-01-31T16:27:42.501-08:002012-01-31T16:27:42.501-08:00Clinicaltrials.gov, an NIH site of registered clin...Clinicaltrials.gov, an NIH site of registered clinical trials, indicates the following:<br />Small trial, of TTF in lung cancer, sponsored by NovoCure Ltd<br />http://clinicaltrials.gov/ct2/show/NCT00749346?term=novocure&rank=2<br />Looks like results haven't been analyzed and/or reported yet<br />Looks like this trial was done in Switzerland<br /><br />The company’s website indicates they’re going to do a trial in patient with non-small cell lung cancer: http://www.novocure.com/clinical_trials.php?ID=1<br />It says: “Lung – Planned<br />Novocure is preparing an IDE submission for a pivotal (phase III) trial of TTF therapy given in combination with chemotherapy for patients with non-small cell lung cancer. Please check back on this website to follow the progress of this clinical program.”<br /><br />Here's a link to a WSJ article on the therapy in brain cancer patients: http://online.wsj.com/article/SB10001424052748703303904575292691538647642.html<br /><br />I have no knowledge of this therapy and am not advocating for it in any way--just providing info.Anonymousnoreply@blogger.com